This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Destiny Pharma Résultats passés
Passé contrôle des critères 0/6
Destiny Pharma's earnings have been declining at an average annual rate of -4.9%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 51.3% per year.
Informations clés
-4.9%
Taux de croissance des bénéfices
10.0%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | 11.5% |
Taux de croissance des recettes | 51.3% |
Rendement des fonds propres | -61.6% |
Marge nette | -680.3% |
Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Jan 12Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans
Sep 26We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully
May 26Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth
Feb 01Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?
Aug 05Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?
Apr 16What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?
Feb 11We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely
Nov 30Ventilation des recettes et des dépenses
Comment Destiny Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Dec 23 | 1 | -6 | 8 | 0 |
30 Sep 23 | 1 | -6 | 8 | 0 |
30 Jun 23 | 1 | -6 | 8 | 0 |
31 Mar 23 | 1 | -6 | 8 | 0 |
31 Dec 22 | 0 | -7 | 8 | 0 |
30 Sep 22 | 0 | -6 | 8 | 0 |
30 Jun 22 | 0 | -6 | 7 | 0 |
31 Mar 22 | 0 | -6 | 7 | 0 |
31 Dec 21 | 0 | -5 | 6 | 0 |
30 Sep 21 | 0 | -5 | 7 | 0 |
30 Jun 21 | 0 | -5 | 7 | 0 |
31 Mar 21 | 0 | -5 | 7 | 0 |
31 Dec 20 | 0 | -5 | 7 | 0 |
30 Sep 20 | 0 | -5 | 6 | 0 |
30 Jun 20 | 0 | -5 | 6 | 0 |
31 Mar 20 | 0 | -5 | 6 | 0 |
31 Dec 19 | 0 | -5 | 6 | 0 |
30 Sep 19 | 0 | -5 | 6 | 0 |
30 Jun 19 | 0 | -5 | 6 | 0 |
31 Mar 19 | 0 | -5 | 6 | 0 |
31 Dec 18 | 0 | -5 | 6 | 0 |
30 Sep 18 | 0 | -5 | 5 | 0 |
30 Jun 18 | 0 | -4 | 4 | 0 |
31 Mar 18 | 0 | -4 | 4 | 0 |
31 Dec 17 | 0 | -3 | 3 | 0 |
30 Sep 17 | 0 | -2 | 2 | 0 |
30 Jun 17 | 0 | -2 | 2 | 0 |
31 Mar 17 | 0 | -1 | 2 | 0 |
31 Dec 16 | 0 | -1 | 1 | 0 |
31 Dec 15 | 0 | -1 | 1 | 0 |
31 Dec 14 | 0 | -2 | 2 | 0 |
Des revenus de qualité: DEST is currently unprofitable.
Augmentation de la marge bénéficiaire: DEST is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: DEST is unprofitable, and losses have increased over the past 5 years at a rate of 4.9% per year.
Accélération de la croissance: Unable to compare DEST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: DEST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.8%).
Rendement des fonds propres
ROE élevé: DEST has a negative Return on Equity (-61.56%), as it is currently unprofitable.